Literature DB >> 15703821

Comparison study of the expressions of myristoylated alanine-rich C kinase substrate in hepatocellular carcinoma, liver cirrhosis, chronic hepatitis, and normal liver.

Tsutomu Masaki1, Masaaki Tokuda, Shuhei Yoshida, Seiji Nakai, Asahiro Morishita, Naohito Uchida, Toshiharu Funaki, Yuko Kita, Fumi Funakoshi, Takako Nonomura, Takashi Himoto, Akihiro Deguchi, Yasuhiko Kimura, Kunihiko Izuishi, Hisao Wakabayashi, Hisashi Usuki, Hitoshi Yoshiji, Seishiro Watanabe, Kazutaka Kurokohchi, Shigeki Kuriyama.   

Abstract

The myristoylated alanine-rich C kinase substrate (MARCKS) is a prominent substrate for protein kinase C (PKC) in a variety of cells. The aim of this study was not only to evaluate the expression and localization of MARCKS in various pathological liver tissues, including HCC, but also to analyze the difference in MARCKS expression between hepatitis virus-induced HCC and cirrhosis. The level of MARCKS and its phosphorylated proteins, as well as its localization, were determined using Western blot and/or immunohistochemistry in HCC and other pathological liver tissues. We also analyzed the change of MARCKS localization on the influence of MARCKS phosphorylation in the HLF cancer cell line by phosphorylation study. In addition, the relationship between MARCKS expression and proliferative activity was studied in HCC. In the immunohistochemical study, a very small amount of MARCKS protein was found along the contour of the hepatocellular membrane in normal liver and in cases of chronic hepatitis. MARCKS was up-regulated in liver cirrhosis tissue and was localized in the cytoplasm of hepatocytes. The expression of MARCKS was down-regulated in HCC tissues, as compared with non-tumorous liver cirrhosis tissues from the same patients. Furthermore, MARCKS was serine-phosphorylated in liver cirrhosis and HCC, and phosphorylated MARCKS was detected in a cytosolic fraction of these tissues. In a phosphorylation study using the HLF HCC cell line, MARCKS was displaced from the plasma membrane to the cytosol following the activation of protein kinase C (PKC) by phorbol 12-myristrate 13-acetate (PMA). Furthermore, the activity of cyclin D1 and cyclin E kinases was found to be higher in HCCs with low MARCKS expression than in HCCs with high MARCKS expression. These results suggest that up-regulation of MARCKS might be essential in the generation of cirrhotic nodules through chronic hepatitis from normal liver, and that the phosphorylation and/or down-regulation of MARCKS might play an important role in the development and progression of HCC from liver cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15703821

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  12 in total

1.  A novel predictor of cancer malignancy: up-regulation of myristoylated alanine-rich C kinase substrate phosphorylation in lung cancer.

Authors:  Ching-Hsien Chen; Chun-Lung Chiu; Kenneth B Adler; Reen Wu
Journal:  Am J Respir Crit Care Med       Date:  2014-04-15       Impact factor: 21.405

2.  miR-34c-3p inhibits cell proliferation, migration and invasion of hepatocellular carcinoma by targeting MARCKS.

Authors:  Jianjun Song; Qi Wang; Yongyun Luo; Peng Yuan; Chaofeng Tang; Yongfeng Hui; Zuozheng Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

3.  Use of protein array technology to investigate receptor tyrosine kinases activated in hepatocellular carcinoma.

Authors:  Shi Liu; Jian Gong; Asahiro Morishita; Takako Nomura; Hisaaki Miyoshi; Joji Tani; Kiyohito Kato; Hirohito Yoneyama; Akihiro Deguchi; Hirohito Mori; Shima Mimura; Kei Nomura; Takashi Himoto; Kazushi Deguchi; Keiichi Okano; Kunihiko Izuishi; Yasuyuki Suzuki; Yoshio Kushida; Reiji Haba; Hisakazu Iwama; Tsutomu Masaki
Journal:  Exp Ther Med       Date:  2011-02-08       Impact factor: 2.447

Review 4.  Pathophysiological roles of myristoylated alanine-rich C-kinase substrate (MARCKS) in hematological malignancies.

Authors:  Deepak Narayanan Iyer; Omar Faruq; Lun Zhang; Nasrin Rastgoo; Aijun Liu; Hong Chang
Journal:  Biomark Res       Date:  2021-05-06

5.  LAP2 is widely overexpressed in diverse digestive tract cancers and regulates motility of cancer cells.

Authors:  Hyun-Jung Kim; Sun-Hwi Hwang; Myoung-Eun Han; Sungmin Baek; Hey-Eun Sim; Sik Yoon; Sun-Yong Baek; Bong-Seon Kim; Jeong-Hwan Kim; Seon-Young Kim; Sae-Ock Oh
Journal:  PLoS One       Date:  2012-06-20       Impact factor: 3.240

6.  Telmisartan inhibits hepatocellular carcinoma cell proliferation in vitro by inducing cell cycle arrest.

Authors:  Kyoko Oura; Tomoko Tadokoro; Shintaro Fujihara; Asahiro Morishita; Taiga Chiyo; Eri Samukawa; Yoshimi Yamana; Koji Fujita; Teppei Sakamoto; Takako Nomura; Hirohito Yoneyama; Hideki Kobara; Hirohito Mori; Hisakazu Iwama; Keiichi Okano; Yasuyuki Suzuki; Tsutomu Masaki
Journal:  Oncol Rep       Date:  2017-09-20       Impact factor: 3.906

7.  The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKα/mTOR pathway in vitro and in vivo.

Authors:  Shintaro Fujihara; Asahiro Morishita; Kana Ogawa; Tomoko Tadokoro; Taiga Chiyo; Kiyohito Kato; Hideki Kobara; Hirohito Mori; Hisakazu Iwama; Tsutomu Masaki
Journal:  Oncotarget       Date:  2017-01-31

8.  miR‑34c‑3p acts as a tumor suppressor gene in osteosarcoma by targeting MARCKS.

Authors:  Hongliang Liu; Pengxiao Su; Liqiang Zhi; Kai Zhao
Journal:  Mol Med Rep       Date:  2017-01-11       Impact factor: 2.952

9.  MARCKS Signaling Differentially Regulates Vascular Smooth Muscle and Endothelial Cell Proliferation through a KIS-, p27kip1- Dependent Mechanism.

Authors:  Dan Yu; George Makkar; Tuo Dong; Dudley K Strickland; Rajabrata Sarkar; Thomas Stacey Monahan
Journal:  PLoS One       Date:  2015-11-03       Impact factor: 3.240

10.  Proteome-wide analyses of human hepatocytes during differentiation and dedifferentiation.

Authors:  Cliff Rowe; Dave T Gerrard; Roz Jenkins; Andrew Berry; Kesta Durkin; Lars Sundstrom; Chris E Goldring; B Kevin Park; Neil R Kitteringham; Karen Piper Hanley; Neil A Hanley
Journal:  Hepatology       Date:  2013-07-01       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.